Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

The effect of time to post-operative weightbearing on functional and clinical outcomes in adults with a displaced intra-articular calcaneal fracture; A systematic review and pooled analysis.

De Boer AS, Van Lieshout EMM, Van Moolenbroek G, Den Hartog D, Verhofstad MHJ.

Injury. 2018 Apr;49(4):743-752. doi: 10.1016/j.injury.2018.02.021. Epub 2018 Feb 21. Review.

PMID:
29496317
2.

Soft tissue complications and timing of surgery in patients with a tongue-type displaced intra-articular calcaneal fracture: An international retrospective cohort study.

De Boer AS, Van Lieshout EMM, Van 't Land F, Misselyn D, Schepers T, Den Hartog D, Verhofstad MHJ.

Injury. 2018 Feb;49(2):425-429. doi: 10.1016/j.injury.2017.12.008. Epub 2017 Dec 11.

PMID:
29248185
3.

Validation of the American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Scale Dutch language version in patients with hindfoot fractures.

De Boer AS, Meuffels DE, Van der Vlies CH, Den Hoed PT, Tuinebreijer WE, Verhofstad MHJ, Van Lieshout EMM; AOFAS Study Group.

BMJ Open. 2017 Nov 14;7(11):e018314. doi: 10.1136/bmjopen-2017-018314.

4.

2D and 3D assessment of sustentaculum tali screw fixation with or without Screw Targeting Clamp.

De Boer AS, Van Lieshout EMM, Vellekoop L, Knops SP, Kleinrensink GJ, Verhofstad MHJ.

Injury. 2017 Dec;48(12):2864-2871. doi: 10.1016/j.injury.2017.10.035. Epub 2017 Oct 26.

PMID:
29102369
5.

The American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Scale; translation and validation of the Dutch language version for ankle fractures.

de Boer AS, Tjioe RJC, Van der Sijde F, Meuffels DE, den Hoed PT, Van der Vlies CH, Tuinebreijer WE, Verhofstad MHJ, Van Lieshout EMM; AOFAS Study Group.

BMJ Open. 2017 Aug 3;7(8):e017040. doi: 10.1136/bmjopen-2017-017040.

6.

Reactive Astrocytes Promote ALS-like Degeneration and Intracellular Protein Aggregation in Human Motor Neurons by Disrupting Autophagy through TGF-β1.

Tripathi P, Rodriguez-Muela N, Klim JR, de Boer AS, Agrawal S, Sandoe J, Lopes CS, Ogliari KS, Williams LA, Shear M, Rubin LL, Eggan K, Zhou Q.

Stem Cell Reports. 2017 Aug 8;9(2):667-680. doi: 10.1016/j.stemcr.2017.06.008. Epub 2017 Jul 14.

7.

American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Score: a study protocol for the translation and validation of the Dutch language version.

Van Lieshout EM, De Boer AS, Meuffels DE, Den Hoed PT, Van der Vlies CH, Tuinebreijer WE, Verhofstad MH.

BMJ Open. 2017 Feb 27;7(2):e012884. doi: 10.1136/bmjopen-2016-012884.

8.

A perspective on stem cell modeling of amyotrophic lateral sclerosis.

de Boer AS, Eggan K.

Cell Cycle. 2015;14(23):3679-88. doi: 10.1080/15384101.2015.1093712. Review.

9.

Correction: A New Approach to Assess the Gastrocnemius Muscle Volume in Rodents Using Ultrasound; Comparison with the Gastrocnemius Muscle Index.

Nijhuis TH, de Boer AS, Wahegaonkar AL, Bishop AT, Shin AY, Hovius SE, Selles RW.

PLoS One. 2015 Jul 20;10(7):e0133944. doi: 10.1371/journal.pone.0133944. eCollection 2015. No abstract available.

10.

Genetic validation of a therapeutic target in a mouse model of ALS.

de Boer AS, Koszka K, Kiskinis E, Suzuki N, Davis-Dusenbery BN, Eggan K.

Sci Transl Med. 2014 Aug 6;6(248):248ra104. doi: 10.1126/scitranslmed.3009351.

11.

Functional outcome and patient satisfaction after displaced intra-articular calcaneal fractures: a comparison among open, percutaneous, and nonoperative treatment.

De Boer AS, Van Lieshout EM, Den Hartog D, Weerts B, Verhofstad MH, Schepers T.

J Foot Ankle Surg. 2015 May-Jun;54(3):298-305. doi: 10.1053/j.jfas.2014.04.014. Epub 2014 Jun 2.

PMID:
24891090
12.

Health care consumption and costs due to foot and ankle injuries in the Netherlands, 1986-2010.

De Boer AS, Schepers T, Panneman MJ, Van Beeck EF, Van Lieshout EM.

BMC Musculoskelet Disord. 2014 Apr 12;15:128. doi: 10.1186/1471-2474-15-128.

13.

Erosion of dosage compensation impacts human iPSC disease modeling.

Mekhoubad S, Bock C, de Boer AS, Kiskinis E, Meissner A, Eggan K.

Cell Stem Cell. 2012 May 4;10(5):595-609. doi: 10.1016/j.stem.2012.02.014.

14.

GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.

Madsen LW, Knauf JA, Gotfredsen C, Pilling A, Sjögren I, Andersen S, Andersen L, de Boer AS, Manova K, Barlas A, Vundavalli S, Nyborg NC, Knudsen LB, Moelck AM, Fagin JA.

Endocrinology. 2012 Mar;153(3):1538-47. doi: 10.1210/en.2011-1864. Epub 2012 Jan 10.

15.

The design of chronic toxicology studies of monoclonal antibodies: implications for the reduction in use of non-human primates.

Chapman KL, Andrews L, Bajramovic JJ, Baldrick P, Black LE, Bowman CJ, Buckley LA, Coney LA, Couch J, Maggie Dempster A, de Haan L, Jones K, Pullen N, de Boer AS, Sims J, Ian Ragan C.

Regul Toxicol Pharmacol. 2012 Mar;62(2):347-54. doi: 10.1016/j.yrtph.2011.10.016. Epub 2011 Nov 6.

PMID:
22100994
16.

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Mølck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M, Moerch U.

Endocrinology. 2010 Apr;151(4):1473-86. doi: 10.1210/en.2009-1272. Epub 2010 Mar 4. Erratum in: Endocrinology. 2012 Feb;153(2):1000. Moerch, Ulrik [added].

PMID:
20203154
17.

Public health and healthcare-associated infections in the Netherlands.

de Boer AS, Coutinho RA.

J Hosp Infect. 2007 Jun;65 Suppl 2:133-8. No abstract available.

PMID:
17540257
18.

Antibiotic prophylaxis and the risk of surgical site infections following total hip arthroplasty: timely administration is the most important factor.

van Kasteren ME, Manniën J, Ott A, Kullberg BJ, de Boer AS, Gyssens IC.

Clin Infect Dis. 2007 Apr 1;44(7):921-7. Epub 2007 Feb 14.

PMID:
17342642
19.

Effect of optimized antibiotic prophylaxis on the incidence of surgical site infection.

Manniën J, van Kasteren ME, Nagelkerke NJ, Gyssens IC, Kullberg BJ, Wille JC, de Boer AS.

Infect Control Hosp Epidemiol. 2006 Dec;27(12):1340-6. Epub 2006 Nov 22.

PMID:
17152032
20.

Improved risk adjustment for comparison of surgical site infection rates.

Geubbels EL, Grobbee DE, Vandenbroucke-Grauls CM, Wille JC, de Boer AS.

Infect Control Hosp Epidemiol. 2006 Dec;27(12):1330-9. Epub 2006 Nov 17.

PMID:
17152031
21.

Incidence and risk factors of device-associated infections and associated mortality at the intensive care in the Dutch surveillance system.

van der Kooi TI, de Boer AS, Manniën J, Wille JC, Beaumont MT, Mooi BW, van den Hof S.

Intensive Care Med. 2007 Feb;33(2):271-8. Epub 2006 Dec 5.

PMID:
17146632
22.

Reduced risk of surgical site infections through surveillance in a network.

Geubbels EL, Nagelkerke NJ, Mintjes-De Groot AJ, Vandenbroucke-Grauls CM, Grobbee DE, De Boer AS.

Int J Qual Health Care. 2006 Apr;18(2):127-33. Epub 2006 Feb 16.

PMID:
16484315
23.

Quality improvement of surgical prophylaxis in Dutch hospitals: evaluation of a multi-site intervention by time series analysis.

van Kasteren ME, Mannien J, Kullberg BJ, de Boer AS, Nagelkerke NJ, Ridderhof M, Wille JC, Gyssens IC.

J Antimicrob Chemother. 2005 Dec;56(6):1094-102. Epub 2005 Oct 18.

PMID:
16234334
24.

Hospital-related determinants for surgical-site infection following hip arthroplasty.

Geubbels EL, Wille JC, Nagelkerke NJ, Vandenbroucke-Grauls CM, Grobbee DE, de Boer AS.

Infect Control Hosp Epidemiol. 2005 May;26(5):435-41.

PMID:
15954480
25.

Adherence to local hospital guidelines for surgical antimicrobial prophylaxis: a multicentre audit in Dutch hospitals.

van Kasteren ME, Kullberg BJ, de Boer AS, Mintjes-de Groot J, Gyssens IC.

J Antimicrob Chemother. 2003 Jun;51(6):1389-96. Epub 2003 May 13.

PMID:
12746377
26.

Exogenous re-infection as a cause of recurrent tuberculosis in a low-incidence area.

de Boer AS, Borgdorff MW, Vynnycky E, Sebek MM, van Soolingen D.

Int J Tuberc Lung Dis. 2003 Feb;7(2):145-52.

PMID:
12588015
27.

An outbreak of diarrhea in a neonatal medium care unit caused by a novel strain of rotavirus: investigation using both epidemiologic and microbiological methods.

Widdowson MA, van Doornum GJ, van der Poel WH, de Boer AS, van de Heide R, Mahdi U, Haanen P, Kool JL, Koopmans M.

Infect Control Hosp Epidemiol. 2002 Nov;23(11):665-70.

PMID:
12452294
28.

False-positive mycobacterium tuberculosis cultures in 44 laboratories in The Netherlands (1993 to 2000): incidence, risk factors, and consequences.

de Boer AS, Blommerde B, de Haas PE, Sebek MM, Lambregts-van Weezenbeek KS, Dessens M, van Soolingen D.

J Clin Microbiol. 2002 Nov;40(11):4004-9.

29.

Risk assessment for surgical site infections following total hip and total knee prostheses.

de Boer AS, Geubbels EL, Wille J, Mintjes-de Groot AJ.

J Chemother. 2001 Nov;13 Spec No 1(1):42-7.

PMID:
11936378
30.

Genetic mutations occur gradually in in vivo populations of Mycobacterium tuberculosis bacteria.

de Boer AS, van Soolingen D, Borgdorff MW.

J Clin Microbiol. 2001 Oct;39(10):3814. No abstract available.

31.

Surveillance of hospital-acquired infection in England, Germany, and The Netherlands: will international comparison of rates be possible?

Coello R, Gastmeier P, de Boer AS.

Infect Control Hosp Epidemiol. 2001 Jun;22(6):393-7.

PMID:
11519923
32.

[Hospital infections and risk factors in the intensive care units of 16 Dutch hospitals, results of surveillance of quality assurance indicators].

Groot AJ, Geubbels EL, Beaumont MT, Wille JC, de Boer AS.

Ned Tijdschr Geneeskd. 2001 Jun 30;145(26):1249-54. Dutch.

PMID:
11455692
33.

Recurrent tuberculosis due to exogenous reinfection.

de Boer AS, van Soolingen D.

N Engl J Med. 2000 Apr 6;342(14):1050-1. No abstract available.

PMID:
10755895
34.

Genetic heterogeneity in Mycobacterium tuberculosis isolates reflected in IS6110 restriction fragment length polymorphism patterns as low-intensity bands.

de Boer AS, Kremer K, Borgdorff MW, de Haas PE, Heersma HF, van Soolingen D.

J Clin Microbiol. 2000 Dec;38(12):4478-84.

35.

Emerging group-A rotavirus and a nosocomial outbreak of diarrhoea.

Widdowson MA, van Doornum GJ, van der Poel WH, de Boer AS, Mahdi U, Koopmans M.

Lancet. 2000 Sep 30;356(9236):1161-2.

PMID:
11030297
36.

[Frequency of postoperative wound infections: an unsuitable parameter for comparison of hospitals].

Geubbels EL, Mintjes-de Groot AJ, de Boer AS, Wille J.

Ned Tijdschr Geneeskd. 2000 May 27;144(22):1085-6. Dutch. No abstract available.

PMID:
10850114
37.
38.

Interpreting DNA fingerprint clusters of Mycobacterium tuberculosis. European Concerted Action on Molecular Epidemiology and Control of Tuberculosis.

Glynn JR, Bauer J, de Boer AS, Borgdorff MW, Fine PE, Godfrey-Faussett P, Vynnycky E.

Int J Tuberc Lung Dis. 1999 Dec;3(12):1055-60.

PMID:
10599007
39.

Analysis of rate of change of IS6110 RFLP patterns of Mycobacterium tuberculosis based on serial patient isolates.

de Boer AS, Borgdorff MW, de Haas PE, Nagelkerke NJ, van Embden JD, van Soolingen D.

J Infect Dis. 1999 Oct;180(4):1238-44.

PMID:
10479153
40.

Risk assessment for surgical-site infections in orthopedic patients.

de Boer AS, Mintjes-de Groot AJ, Severijnen AJ, van den Berg JM, van Pelt W.

Infect Control Hosp Epidemiol. 1999 Jun;20(6):402-7.

PMID:
10395141
41.

[Secondary infection with methacillin resistant Staphylococcus aureus in Dutch hospitals (July 1997-June 1996].

Esveld MI, de Boer AS, Notenboom AJ, van Pelt W, van Leeuwen WJ.

Ned Tijdschr Geneeskd. 1999 Jan 23;143(4):205-8. Dutch.

PMID:
10086143
42.

[Incidence of postoperative wound infections in The Netherlands].

Mintjes-de Groot AJ, van den Berg JM, Veerman-Brenzikofer ML, de Boer AS, Smook AO.

Ned Tijdschr Geneeskd. 1998 Jan 3;142(1):22-6. Dutch.

PMID:
9556985
43.

An outbreak of cryptosporidiosis in the Netherlands.

Van Asperen IA, Mank T, Medema GJ, Stijnen C, De Boer AS, Groot JF, TenHam P, Sluiters JF, Borgdorff MW.

Euro Surveill. 1996 Feb;1(2):11-12.

PMID:
12631742
44.

Nutritional aspects of changes in disease patterns in the Western Pacific region.

Cavalli-Sforza LT, Rosman A, de Boer AS, Darnton-Hill I.

Bull World Health Organ. 1996;74(3):307-18. Review.

45.

An overview of the safety evaluation of the Rhizomucor miehei lipase enzyme.

Broadmeadow A, Clare C, De Boer AS.

Food Addit Contam. 1994 Jan-Feb;11(1):105-19. Review.

PMID:
8181628
46.

A good start in life: breast-feeding in hospital.

de Boer AS, Darnton-Hill I.

World Health Forum. 1994;15(1):66-8.

PMID:
8141984
47.

Toxicological Evaluation of Acetolactate Decarboxylase.

DE Boer AS, Marshall R, Broadmeadow A, Hazelden K.

J Food Prot. 1993 Jun;56(6):510-517. doi: 10.4315/0362-028X-56.6.510.

PMID:
31084184
48.

On the safety of Bacillus subtilis and B. amyloliquefaciens: a review.

de Boer AS, Diderichsen B.

Appl Microbiol Biotechnol. 1991 Oct;36(1):1-4. Review. No abstract available.

PMID:
1367772
49.

Determining the Safety of Maltogenic Amylase Produced by rDNA Technology.

Andersen JR, Diderichsen BK, Hjortkjaer RK, DE Boer AS, Bootman J, West H, Ashby R.

J Food Prot. 1987 Jun;50(6):521-526. doi: 10.4315/0362-028X-50.6.521.

PMID:
30965448

Supplemental Content

Loading ...
Support Center